サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1439991

原薬（API）- 世界市場の考察、競合情勢、市場予測（2030年）

Active Pharmaceutical Ingredient (API) - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
原薬（API）- 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の原薬（API）の市場規模は、2020年に1,850億米ドル、2030年までに2,867億9,000万米ドルに達し、2024年～2030年の予測期間にCAGRで7.64％の成長が見込まれます。市場は、さまざまな疾患の流行、老年人口の増加、医薬品開発への注目の高まり、生物学的製剤の人気向上などの要因により、前向きな市場成長を示しています。

原薬（API）の市場力学

API市場の主な促進要因の1つは、さまざまな疾患の流行です。糖尿病と高血圧は、合成医薬品が処方されるもっとも一般的な適応症の2つです。International Diabetes Federationの統計によると、2022年に20～79歳の成人約5億3,700万人が糖尿病を患っています。同様に、世界保健機関（WHO）（2023）が提供した別のデータでは、コレステロールの上昇は260万人の死亡を引き起こすと推定されています。先進国でも発展途上国でも、虚血性心疾患や脳卒中の危険因子として、疾病負担の主な原因と考えられています。上記の適応症は、虚血性心疾患、緑内障、がんなどの他の疾患や症候群の主な危険因子でもあります。メトホルミン、アトルバスタチン、エナラプリルなどの合成医薬品は、上記の適応症に対する一般的な医薬品として処方されています。したがって、さまざまな病因の疾患を含むさまざまな疾患の流行は、疾患の管理に用いる医薬品の需要を促進し、ひいては原薬（API）の需要に寄与すると予測され、それによって予測期間（2024年～2030年）の世界の原薬（API）市場の成長にプラスの影響を与える見込みです。

API市場の成長をもたらすもう1つの主な要因は、医薬品開発への注目の高まりです。疾病数の増加を考慮し、新治療法の研究開発に注目が集まっています。その結果、医薬品や生物学的製剤などの新製品が発売されるようになっています。さらに、買収や提携、地域拡大の増加は、医薬品製造に携わるメーカーが確保した戦略的取り組みの一部であり、世界のAPI市場を後押ししました。例えば、Quartic.aiとBright Path Labsは2020年、重要な低分子医薬品の製造に必要不可欠な原薬（API）の継続的な製造に向けたAIベース技術を開発するために提携しました。したがって、このような施策は今後、API市場を牽引していくと予測されます。

しかし、製造と承認プロセスに関する厳しい規制ガイドラインや高い投資コストが、API市場の成長を抑制する可能性があります。

原薬（API）市場は、COVID-19の蔓延を抑えるために必要な措置としてロックダウン規制が課されたため、市場成長が一時的に阻害された時期がありました。抗生物質、抗ウイルス剤、呼吸器薬の需要が増加していたにもかかわらず、ロックダウン措置はサプライチェーンに多大な影響を与え、生産に混乱をもたらしました。しかし、製薬部門を含む産業全体の活動が再開されたことで、2024年～2030年の予測期間の原薬（API）市場は向上しています。

原薬（API）市場のセグメント分析

原薬（API）市場の合成タイプセグメントでは、バイオテクノロジーカテゴリが予測期間（2024年～2030年）に原薬（API）市場のCAGRでより速い成長を記録する見込みです。これは遺伝性疾患の流行によるものと考えられ、生物学的製剤は従来の化学的製剤に比べて有益であることが証明されています。例えば、遺伝子治療に基づく生物学的製剤は、がん、血友病、高コレステロール血症、神経変性疾患などの遺伝性疾患において、遺伝子の置換やノックダウンからワクチン接種まで幅広い用途があります。さらに、生物学的製剤は従来の低分子薬とは異なり、標的特異的に作用するため、関節リウマチのような自己免疫疾患やさまざまなタイプのがんの治療薬として好まれています。したがって、生物学的製剤に関連する利点を考慮すると、この製品カテゴリは予測期間にCAGRの成長が加速し、結果として世界の原薬（API）市場全体の成長に寄与すると予測されます。

当レポートでは、世界の原薬（API）市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 API市場レポートのイントロダクション

第2章 API市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価
  • 財務ベンチマーク

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 API市場の主な要因の分析

  • API市場の促進要因
  • API市場の抑制要因と課題
  • API市場の機会

第5章 API市場のポーターのファイブフォース分析

第6章 API市場に対するCOVID-19の影響分析

第7章 API市場のレイアウト

  • タイプ別
    • 革新的
    • ジェネリック
  • メーカータイプ別
    • 自社
    • 外販
  • 合成タイプ別
    • 合成
    • バイオテクノロジー
  • 用途タイプ別
    • 腫瘍
    • 心臓
    • 呼吸器
    • 神経
    • 眼科
    • その他
  • 地域
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 API市場：世界の企業シェア分析 - 主要3～5社

第9章 API市場の企業と製品のプロファイル

  • Aurobindo Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc
  • Novartis AG
  • BASF SE
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd
  • Lupin Ltd.
  • Viatris
  • Sun Pharmaceutical Industries Ltd
  • Merck KGaA
  • AbbVie Inc
  • Bristol Myers-Squibb Company
  • Cipla Inc
  • Divi's Laboratories Limited
  • GlaxoSmithKline plc
  • Albemarle Corporation
  • Orion Corporation
  • Fidia Farmaceutici s.p.a
  • AstraZeneca

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1 Competitive Analysis
  • Table 2 COVID-19 Impact Analysis
  • Table 3 API Market in Global (2018-2030)
  • Table 4 API Market in Global by Type (2018-2030)
  • Table 5 API Market in Global by Manufacturer Type (2018-2030)
  • Table 6 API Market in Global by Synthesis Type (2018-2030)
  • Table 7 API Market in Global by Application (2018-2030)
  • Table 8 API Market in Global by Geography (2018-2030)
  • Table 9 API Market in North America (2018-2030)
  • Table 10 API Market in North America by Type (2018-2030)
  • Table 11 API Market in North America by Manufacturer Type (2018-2030)
  • Table 12 API Market in North America by Synthesis Type (2018-2030)
  • Table 13 API Market in North America by Application (2018-2030)
  • Table 14 API Market in North America by Country (2018-2030)
  • Table 15 API Market in the US (2018-2030)
  • Table 16 API Market in Canada (2018-2030)
  • Table 17 API Market in Mexico (2018-2030)
  • Table 18 API Market in Europe (2018-2030)
  • Table 19 API Market in Europe by Type (2018-2030)
  • Table 20 API Market in Europe by Manufacturer Type (2018-2030)
  • Table 21 API Market in Europe by Synthesis Type (2018-2030)
  • Table 22 API Market in Europe by Application (2018-2030)
  • Table 23 API Market in Europe by Country (2018-2030)
  • Table 24 API Market in France (2018-2030)
  • Table 25 API Market in Germany (2018-2030)
  • Table 26 API Market in the United Kingdom (2018-2030)
  • Table 27 API Market in Italy (2018-2030)
  • Table 28 API Market in Spain (2018-2030)
  • Table 29 API Market in Russia (2018-2030)
  • Table 30 API Market in Rest of Europe (2018-2030)
  • Table 31 API Market in APAC (2018-2030)
  • Table 32 API Market in APAC by Type (2018-2030)
  • Table 33 API Market in APAC by Manufacturer Type (2018-2030)
  • Table 34 API Market in APAC by Synthesis Type (2018-2030)
  • Table 35 API Market in APAC by Application (2018-2030)
  • Table 36 API Market in APAC by Country (2018-2030)
  • Table 37 API Market in China (2018-2030)
  • Table 38 API Market in Japan (2018-2030)
  • Table 39 API Market in India (2018-2030)
  • Table 40 API Market in Australia (2018-2030)
  • Table 41 API Market in South Korea (2018-2030)
  • Table 42 API Market in Rest of APAC (2018-2030)
  • Table 43 API Market in Rest of World (2018-2030)
  • Table 44 API Market in RoW by Type (2018-2030)
  • Table 45 API Market in RoW by Manufacturer Type (2018-2030)
  • Table 46 API Market in RoW by Synthesis Type (2018-2030)
  • Table 47 API Market in RoW by Application (2018-2030)
  • Table 48 API Market in RoW by Region (2018-2030)
  • Table 49 API Market in Middle East (2018-2030)
  • Table 50 API Market in Africa (2018-2030)
  • Table 51 API Market in South America (2018-2030)

List of Figures

  • Figure 1 Competitive Analysis
  • Figure 2 COVID-19 Impact Analysis
  • Figure 3 API Market in Global (2018-2030)
  • Figure 4 API Market in Global by Type (2018-2030)
  • Figure 5 API Market in Global by Manufacturer Type (2018-2030)
  • Figure 6 API Market in Global by Synthesis Type (2018-2030)
  • Figure 7 API Market in Global by Application (2018-2030)
  • Figure 8 API Market in Global by Geography (2018-2030)
  • Figure 9 API Market in North America (2018-2030)
  • Figure 10 API Market in North America by Type (2018-2030)
  • Figure 11 API Market in North America by Manufacturer Type (2018-2030)
  • Figure 12 API Market in North America by Synthesis Type (2018-2030)
  • Figure 13 API Market in North America by Application (2018-2030)
  • Figure 14 API Market in North America by Country (2018-2030)
  • Figure 15 API Market in the US (2018-2030)
  • Figure 16 API Market in Canada (2018-2030)
  • Figure 17 API Market in Mexico (2018-2030)
  • Figure 18 API Market in Europe (2018-2030)
  • Figure 19 API Market in Europe by Type (2018-2030)
  • Figure 20 API Market in Europe by Manufacturer Type (2018-2030)
  • Figure 21 API Market in Europe by Synthesis Type (2018-2030)
  • Figure 22 API Market in Europe by Application (2018-2030)
  • Figure 23 API Market in Europe by Country (2018-2030)
  • Figure 24 API Market in France (2018-2030)
  • Figure 25 API Market in Germany (2018-2030)
  • Figure 26 API Market in the United Kingdom (2018-2030)
  • Figure 27 API Market in Italy (2018-2030)
  • Figure 28 API Market in Spain (2018-2030)
  • Figure 29 API Market in Russia (2018-2030)
  • Figure 30 API Market in Rest of Europe (2018-2030)
  • Figure 31 API Market in APAC (2018-2030)
  • Figure 32 API Market in APAC by Type (2018-2030)
  • Figure 33 API Market in APAC by Manufacturer Type (2018-2030)
  • Figure 34 API Market in APAC by Synthesis Type (2018-2030)
  • Figure 35 API Market in APAC by Application (2018-2030)
  • Figure 36 API Market in APAC by Country (2018-2030)
  • Figure 37 API Market in China (2018-2030)
  • Figure 38 API Market in Japan (2018-2030)
  • Figure 39 API Market in India (2018-2030)
  • Figure 40 API Market in Australia (2018-2030)
  • Figure 41 API Market in South Korea (2018-2030)
  • Figure 42 API Market in Rest of APAC (2018-2030)
  • Figure 43 API Market in Rest of World (2018-2030)
  • Figure 44 API Market in RoW by Type (2018-2030)
  • Figure 45 API Market in RoW by Manufacturer Type (2018-2030)
  • Figure 46 API Market in RoW by Synthesis Type (2018-2030)
  • Figure 47 API Market in RoW by Application (2018-2030)
  • Figure 48 API Market in RoW by Region (2018-2030)
  • Figure 49 API Market in Middle East (2018-2030)
  • Figure 50 API Market in Africa (2018-2030)
  • Figure 51 API Market in South America (2018-2030)
  • Figure 52 Market Drivers
  • Figure 53 Market Barriers
  • Figure 54 Marker Opportunities
  • Figure 55 PORTER'S Five Force Analysis
目次
Product Code: DISR0027

Active Pharmaceutical Ingredient (API) Market By Type (Innovative And Generic), By Manufacturer Type (Captive And Merchant), By Synthesis Type (Synthetic And Biotech), By Application (Oncology, Cardiology, Pulmonology, Neurology, Orthopedic, Opthalmology, And Others), by geography is estimated to register growth at remarkable CAGR forecast till 2030 owing to rising prevalence of various diseases such as diabetes and growing focus on drug development

Global active pharmaceutical ingredient market was valued at USD 185.00 billion in 2020, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 286.79 billion by 2030. The API market is witnessing a positive market growth owing to the factors such as prevalence of various diseases, growing geriatric population, increasing focus on drug development, and rising popularity of biologic drugs among others.

Active Pharmaceutical Ingredients Market Dynamics:

One of the main drivers of the API market is the rising prevalence of various diseases. Diabetes and hypertension are two of the most common indications for which synthetic drugs are prescribed. As per the statistics provided by the International Diabetes Federation, in 2022 near about 537 million adults in the age group of 20-79 years are presently living with diabetes. Similarly, in another data provided by the World Health Organization (2023), raised cholesterol is estimated to cause 2.6 million fatalities. It is considered as a major cause of disease burden in both the developed and developing world as a risk factor for ischemic heart disease and stroke. The indications mentioned above consist as major risk factors for other diseases and syndromes such as ischemic heart disease, glaucoma, cancer among others. Synthetically synthesized pharmaceutical drugs such as metformin, atorvastatin, and enalapril among others that are prescribed as popular pharmaceutical treatment for the above-mentioned indications. Therefore, the rising prevalence of various diseases encompassing diseases of various etiologies are expected to drive the demand for pharmaceutical drugs for disease management which in turn is expected to contribute in the demand for APIs, thereby positively impacting the global active pharmaceutical ingredients market growth during the forecast period (2024-2030).

Another key factor responsible for the growth of the APIs market is the rising focus on drug development. Considering the rise in number of diseases, there has been a growing focus on the research and development of newer therapeutics. This has resulted in the launch of new products such as drugs and biological products. Furthermore, an increase in acquisitions, collaborations, and regional expansions are some of the strategic initiatives ensured by the manufacturers involved in drug manufacturing helped boost the global API market. For instance, Quartic.ai and Bright Path Labs entered into a collaboration in 2020 to develop AI-based technology for continuous manufacturing of critical APIs that are required for producing crucial small-molecule drugs. Therefore, such measures are expected to drive the market for APIs in coming future.

However, stringent regulatory guidelines for the manufacture and approval process and high investment costs may limit the growth of API market.

The active pharmaceutical ingredient market witnessed a period of temporary hindrance in market growth due to the imposing of the lockdown restrictions as necessary measures to contain the COVID-19 spread. The imposing of lockdown massively affected the supply chains and production disruptions despite an increase in the demand for antibiotics, antivirals, and respiratory drugs, thereby limiting the market growth for a short time as well as exhibited a few long-term effects. However, with the resumption of activities across industries including the pharmaceutical sector has been uplifting for the API market during the forecast period from 2024-2030.

Active Pharmaceutical Ingredients Market Segment Analysis:

Active Pharmaceutical Ingredient (API) Market by Type (Innovative and Generic), by Manufacturer Type (Captive and Merchant), by Synthesis Type (Synthetic and Biotech), by Manufacturer Type (Oncology, Cardiology, Pulmonology, Neurology, Orthopedic, Ophthalmology, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the synthesis type segment of the active pharmaceutical ingredients market, the biotech category is projected to register a faster growth in terms of CAGR in the API market during the forecast period (2024-2030). This can be attributed to the rising prevalence of genetic disorders where in biologic drugs have proven to be beneficial compared to conventional chemical drugs. For instance, gene therapy-based biologics have a wide range of applications, from gene replacement and knockdown to vaccination in genetic diseases such as cancer, hemophilia, hypercholesterolemia, and neurodegenerative diseases. Additionally, biologics are being preferred as therapy in autoimmune diseases such as rheumatoid arthritis and different cancer types due to their target-specific action unlike conventional small-molecule drugs. Therefore, considering the advantages associated with biologic drugs, this product category is expected to witness a faster CAGR growth eventually contributing the overall growth of the global active pharmaceutical ingredients market during the forecast period.

Asia-Pacific is expected to register fastest growth in the overall Active Pharmaceutical Ingredients Market:

Among all the regions, Asia-Pacific (APAC) is expected to register the fastest growth in revenue generation in the global API market. This can be ascribed to the large presence of patient pool, growing interest in the APAC region as a manufacturing hub, rising population of the elderly, among other factors in the region.

One of the key factors supporting the growth of the APAC active pharmaceutical ingredients market is the growing interest in the APAC countries as a manufacturing hub for pharmaceutical industry. Asia and the Association of Southeast Asian Nations (ASEAN) region have been emerging as attractive alternatives for companies owing to lower costs, the availability of labor and its status as an established manufacturing base. Several companies are investing to establish manufacturing operations across various sectors in APAC countries such as Thailand, Vietnam, and India. Governments of several nations in the region are also increasingly working towards providing opportunities to attract manufacturers by offering land, tax benefits, and other incentives. Countries in the region have also entered into several free trade agreements (FTA) and partnerships thereby enabling manufacturers to consider these countries as viable hubs for export. Therefore, such measures by the national governments of countries in the APAC region are expected to bolster the growth of the APAC API market during the forecast period.

Owing to such efforts, presently, the greatest concentrations of API manufacturers are located around Asia, specifically in India and China. This has led to more companies outsourcing API manufacturing to such places, which has the main benefit of eliminating the need to invest in highly expensive equipment and infrastructure.

India, for example, is one of the largest pharmaceutical manufacturers in the world. The country has an outstanding position in the global pharmaceutical market and is also the only country in the world with the largest number of US Food and Drug Administration (USFDA) pharmaceutical factories outside the United States. The country is also the world's third largest market for active pharmaceutical ingredients (APIs), producing over 500 different APIs and providing 57% of the APIs to the World Health Organization (WHO) pre-certification list.

Therefore, such factors coupled with rising patient population encompassing the end users of these formulations and increasing focus on healthcare are expected to contribute in the regional growth of the API market in the APAC region.

Active Pharmaceutical Ingredients Market Key Players:

Some of the key market players operating in the active pharmaceutical ingredients market includes Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Viatris, Sun Pharmaceutical Industries Ltd, Merck KGaA, AbbVie Inc., Bristol Myers-Squibb Company, Cipla Inc, Divi's Laboratories Limited, GlaxoSmithKline plc, Albemarle Corporation, Orion Corporation, Fidia Farmaceutici s.p.a., AstraZeneca, and others.

Recent Developmental Activities in Active Pharmaceutical Ingredients Market:

In December 2022, Novasep, announced a Euro 6 million investment on its Chasse-sur-Rhone site, France. This investment is made with the aim to increase and modernize their manufacturing capabilities to support new generation Active Pharmaceutical Ingredients (APIs), in areas such as central nervous system (CNS), oncology, and infectious diseases.

In April 2022, Novartis NVS signed an initial agreement with Roche RHHBY Ensuring capacity and technology transfer for the production of active pharmaceutical ingredients (APIs) for rheumatoid arthritis, Actemra/RoActemra (tocilizumab).

Key Takeaways from the Active Pharmaceutical Ingredients Market Report Study

  • Market size analysis for current API market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the API market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global API market.
  • Various opportunities available for the other competitor in the API market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current API market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for API market growth in the coming future?

Target Audience who can be benefited from this Active Pharmaceutical Ingredients Market Report Study

  • API products providers
  • Research organizations and consulting companies
  • API-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in API
  • Various End-users who want to know more about the API market and latest technological developments in the API market.

Frequently Asked Questions for Active Pharmaceutical Ingredients Market:

1. What is an active pharmaceutical agent?

An active pharmaceutical ingredient (API) is any substance or mixture of substances used in a finished pharmaceutical product (FPP) which is intended to provide pharmacological action.

2. What is the market for Global API?

Global API market was valued at USD 185.00 billion in 2020, growing at a CAGR of 7.64% during the forecast period from 2024 to 2030 to reach USD 286.79 billion by 2030.

3. What are the drivers for Global API Market?

The API market is witnessing a positive market growth owing to the factors such as prevalence of various diseases, growing geriatric population, increasing focus on drug development, and rising popularity of biologic drugs among others.

4. Who are the key players operating in Global API Market?

Some of the key market players operating in the active pharmaceutical ingredients market includes Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Viatris, Sun Pharmaceutical Industries Ltd, Merck KGaA, AbbVie Inc., Bristol Myers-Squibb Company, Cipla Inc, Divi's Laboratories Limited, GlaxoSmithKline plc, Albemarle Corporation, Orion Corporation, Fidia Farmaceutici s.p.a., AstraZeneca, and others.

5. Which region would exhibit fastest growth in API Market?

Asia-Pacific (APAC) is expected to register the fastest growth in revenue generation in the global API market. This can be ascribed to the large presence of patient pool, growing interest in the APAC region as a manufacturing hub, rising population of the elderly, among other factors in the region.

Table of Contents

1.API Market Report Introduction

2.API Market Executive Summary

  • 2.1 Scope of the Study
  • 2.2 Market at Glance
  • 2.3 Competitive Assessment
  • 2.4 Financial Benchmarking

3. Regulatory and Patent Analysis

  • 3.1 The United States
  • 3.2 Europe
  • 3.3 Japan
  • 3.4 China

4. API Market Key Factors Analysis

  • 4.1 API Market Drivers
    • 4.1.1 Increasing Prevalence of Various Diseases
    • 4.1.2 Rising Geriatric Population
    • 4.1.3 Increasing Focus on Drug Development
    • 4.1.4 Rising Popularity of Biologic Drugs
  • 4.2 API Market Restraints and Challenges
    • 4.2.1 Stringent Regulatory Guidelines for API Production and Approval
    • 4.2.2 High Investment Costs
  • 4.3 API Market Opportunities
    • 4.3.1 Introduction of Global Regulatory Pathway for API Approval
    • 4.3.2 Redesigning Global Supply Chains

5. API Market Porter's Five Forces Analysis

  • 5.1 Bargaining Power of Suppliers
  • 5.2 Bargaining Power of Consumers
  • 5.3 Threat of New Entrants
  • 5.4 Threat of Substitutes
  • 5.5 Competitive Rivalry

6. COVID-19 Impact Analysis on API Market

7. API Market Layout

  • 7.1 By Type
    • 7.1.1 Innovative
    • 7.1.2 Generic
  • 7.2 By Manufacturer Type
    • 7.2.1 Captive
    • 7.2.2 Merchant
  • 7.3 By Synthesis Type
    • 7.3.1 Synthetic
    • 7.3.2 Biotech
  • 7.4 By Application Type
    • 7.4.1 Oncology
    • 7.4.2 Cardiology
    • 7.4.3 Pulmonology
    • 7.4.4 Neurology
    • 7.4.5 Ophthalmology
    • 7.4.6 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 North America API Market, by Type
      • 7.5.1.2 North America API Market, by Manufacturer Type
      • 7.5.1.3 North America API Market, by Synthesis Type
      • 7.5.1.4 North America API Market, by Application
      • 7.5.1.5 North America API Market, by Country
      • 7.5.1.3.1 United States
      • 7.5.1.3.2 Canada
      • 7.5.1.3.3 Mexico
    • 7.5.2 Europe
      • 7.5.2.1 Europe API Market, by Type
      • 7.5.2.2 Europe API Market, by Manufacturer Type
      • 7.5.2.3 Europe API Market, by Synthesis Type
      • 7.5.2.4 Europe API Market, by Application
      • 7.5.2.5 Europe API Market, by Country
      • 7.5.2.3.1 France
      • 7.5.2.3.2 Germany
      • 7.5.2.3.3 United Kingdom
      • 7.5.2.3.4 Italy
      • 7.5.2.3.5 Spain
      • 7.5.2.3.6 Russia
      • 7.5.2.3.7 Rest of Europe
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 Asia-Pacific API Market, by Type
      • 7.5.3.2 Asia-Pacific API Market, by Manufacturer Type
      • 7.5.3.3 Asia-Pacific API Market, by Synthesis Type
      • 7.5.3.4 Asia-Pacific API Market, by Application
      • 7.5.3.5 Asia-Pacific API Market, by Country
      • 7.5.3.3.1 China
      • 7.5.3.3.2 Japan
      • 7.5.3.3.3 India
      • 7.5.3.3.4 Australia
      • 7.5.3.3.5 South Korea
      • 7.5.3.3.6 Rest of Asia Pacific
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 RoW API Market, by Type
      • 7.5.4.2 RoW API Market, by Manufacturer Type
      • 7.5.4.3 RoW API Market, by Synthesis Type
      • 7.5.4.4 RoW API Market, by Application
      • 7.5.4.5 RoW API Market, by Region
      • 7.5.4.3.1 Middle East
      • 7.5.4.3.2 Africa
      • 7.5.4.3.3 South America

8. API Market Global Company Share Analysis - Key 3-5 Companies

9. API Market Company and Product Profiles

  • 9.1 Aurobindo Pharma
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4 Product Listing
    • 9.1.5. Entropy
  • 9.2 Teva Pharmaceutical Industries Ltd.
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4 Product Listing
    • 9.2.5. Entropy
  • 9.3 Pfizer Inc
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4 Product Listing
    • 9.3.5. Entropy
  • 9.4 Novartis AG
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4 Product Listing
    • 9.4.5. Entropy
  • 9.5 BASF SE
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4 Product Listing
    • 9.5.5. Entropy
  • 9.6 Boehringer Ingelheim GmbH
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4 Product Listing
    • 9.6.5. Entropy
  • 9.7 Dr. Reddy's Laboratories Ltd
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4 Product Listing
    • 9.7.5. Entropy
  • 9.8 Lupin Ltd.
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4 Product Listing
    • 9.8.5. Entropy
  • 9.9 Viatris
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4 Product Listing
    • 9.9.5. Entropy
  • 9.10 Sun Pharmaceutical Industries Ltd
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4 Product Listing
    • 9.10.5. Entropy
  • 9.11 Merck KGaA
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4 Product Listing
    • 9.11.5. Entropy
  • 9.12 AbbVie Inc
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4 Product Listing
    • 9.12.5. Entropy
  • 9.13 Bristol Myers-Squibb Company
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4 Product Listing
    • 9.13.5. Entropy
  • 9.14 Cipla Inc
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4 Product Listing
    • 9.14.5. Entropy
  • 9.15 Divi's Laboratories Limited
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4 Product Listing
    • 9.15.5. Entropy
  • 9.16 GlaxoSmithKline plc
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4 Product Listing
    • 9.16.5. Entropy
  • 9.17 Albemarle Corporation
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4 Product Listing
    • 9.17.5. Entropy
  • 9.18 Orion Corporation
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4 Product Listing
    • 9.18.5. Entropy
  • 9.19 Fidia Farmaceutici s.p.a
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4 Product Listing
    • 9.19.5. Entropy
  • 9.20 AstraZeneca
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4 Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us